Neuroplasticity Failure in Alzheimer's Disease

Slides:



Advertisements
Similar presentations
Alzheimer’s Disease Edwin Onattu P. 3.
Advertisements

Etiopathogenesis of Alzheimer's disease
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Alzheimer’s Disease By: Ryan Triplett. Alzheimer’s The deterioration of intellectual capabilities, memory, judgment, and personality to the extent that.
Gender Difference in Alzheimer’s Disease Neuropathology EH Corder, E Ghebremedhin, M Taylor, DR Thal, TG Ohm, H Braak Dr. Senckenbergische Anatomie Department.
Comparison of Plaque Burden in Tg2576 Mice Using the Aperio and TurboScan Imaging Platforms A.J. Milici.
Clear organic causes, where primary symptom is a significant deficit in cognitive ability changes in the person’s personality and behavior (due to the.
Amnesia Syndromes Lesson 22. Wernicke-Korsakoff’s Syndrome n Deficits similar to H.M. l Anterograde l retrograde more severe n Cause: Long-term alcohol.
COST CM1103 Training School Structure-based drug design for diagnosis and treatment of neurological diseases Istanbul, 9-13 Sept 2013 Mirjana Babić, mag.biol.mol.
WHAT DO YOU REMEMBER ABOUT ALZHEIMER’S DEMENTIA?.
Introduction Alzheimer’s disease (AD) is a neurodegenerative disease associated with brain shrinkage and the loss of neurons, particularly cholinergic.
Molecular mechanism for Alzheimer’s disease : searching for the possible therapeutic targets Sungkwon Chung Dept. of Physiology Sungkyunkwan Univ. School.
Dr. Usman Ghani CNS Block.  Pathophysiology of alzheimer’s disease: 5I.
The Pathobiology of Vascular Dementia Costantino Iadecola Neuron Volume 80, Issue 4, Pages (November 2013) DOI: /j.neuron Copyright.
?v=pQO3Tq3KQL4 ohlTE.
Dr. Sigal fleisher-Berkovich Neuroinflammation is regulated by angiotensin related drugs: possible implications for neurodegenerative diseases.
Neurobiology of Dementia Majid Barekatain, M.D., Associate Professor of Psychiatry Neuropsychiatrist Isfahan University of Medical Sciences Ordibehesht.
Cultured Schwann Cells Constitutively Express the Myelin Protein P0 Lili Cheng, Anne W Mudge Neuron Volume 16, Issue 2, Pages (February 1996) DOI:
Apolipoprotein E and Gray Matter Loss in Mild Cognitive Impairment and Alzheimer’s Disease Spampinato MV, Goldsberry G, Mintzer J, Rumboldt Z Medical University.
2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.
Mosaic Analysis with a Repressible Cell Marker for Studies of Gene Function in Neuronal Morphogenesis Tzumin Lee, Liqun Luo Neuron Volume 22, Issue 3,
Stage B, a Pre-cursor of Heart Failure Jay N. Cohn, MD, Gary S. Francis, MD Heart Failure Clinics Volume 8, Issue 1, Pages xvii-xviii (January 2012) DOI:
Norton-scientificcollection.com/collection. HEALTH NEWS Bapineuzumab, the treatment being developed by Elan, Johnson & Johnson and Pfizer for Alzheimer’s.
Date of download: 7/7/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Absence of β-Amyloid Deposits After Immunization in.
Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Reduction of SorLA/LR11, a Sorting Protein Limiting.
Alzheimer Disease Dementia: an acquired, generalized, and often progressive impairment of cognitive function that affects the content, but not the level.
Copyright © 1999 American Medical Association. All rights reserved.
Copyright © 2004 American Medical Association. All rights reserved.
Alzheimer’s Disease Dr. Usman Ghani CNS Block.
Alzheimer’s Disease CNS Block.
Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Alzheimer's disease drug development pipeline: 2017
Neurodegeneration caused by prions. A
Small section of the neocortex from a patient with Alzheimer disease showing two classical neuropathologic lesions of the disease. A. The modified silver.
Volume 2, Issue 1, Pages (January 2016)
Imaging AD Progression Amyloid Imaging Agents.
The Neuropathology and Neurobiology of Traumatic Brain Injury
65 year-old female with Alzheimer’s disease
Alzheimer Disease Mayo Clinic Proceedings
Amnesia Syndromes Lecture 21.
The Neuropathology and Neurobiology of Traumatic Brain Injury
Q: How can we prevent or treat Alzheimer’s Disease?
Disorders with Complex Genetics
Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease  Jonathan Cedernaes, Ricardo S. Osorio, Andrew.
Alzheimer's disease drug development pipeline: 2018
Reisa Sperling, Elizabeth Mormino, Keith Johnson  Neuron 
Protein Networks in Alzheimer’s Disease
Acetylation Unleashes Protein Demons of Dementia
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Testing the Amyloid Hypothesis with a Humanized AD Mouse Model
Probing the Biology of Alzheimer's Disease in Mice
Pathways to Primary Neurodegenerative Disease
Mechanisms of Neuronal Degeneration in Alzheimer's Disease
Structural Neurology: Are Seeds at the Root of Neuronal Degeneration?
Todd E. Golde, Lon S. Schneider, Edward H. Koo  Neuron 
The Role of Apolipoprotein E in Alzheimer's Disease
Scott A. Small, Karen Duff  Neuron 
Volume 70, Issue 11, Pages (December 2006)
Volume 16, Issue 21, Pages R906-R910 (November 2006)
Calcification of the Coronary Artery
[18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid-β.
Alzheimer’s Disease Dr. Usman Ghani Neuropsychiatry Block.
How does brain insulin resistance develop in Alzheimer's disease?
Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease  W. Robert Bell, Yang An,
A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis  Caitlin S. Latimer, Carol A. Shively,
Volume 50, Issue 2, Pages iii-iv (April 2019)
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.
Neurodegenerative Tauopathies
Dendritic Tau in Alzheimer’s Disease
Presentation transcript:

Neuroplasticity Failure in Alzheimer's Disease M.-Marsel Mesulam  Neuron  Volume 24, Issue 3, Pages 521-529 (November 1999) DOI: 10.1016/S0896-6273(00)81109-5

Figure 1 The Progression of NFT in Time and Space and Their Relationship to the Clinical State One, two, three, and four plus signs refer to low, medium, high, and very high densities of NFT, respectively. The low limbic stage corresponds stages I and II of Braak and Braak 1996, the high limbic stage to their stages III and IV, the low neocortical stage to their stage V, and the high neocortical stage to their stage VI. Neuron 1999 24, 521-529DOI: (10.1016/S0896-6273(00)81109-5)

Figure 2 Multiple Factors Increase the Neuroplasticity Burden Eventually, the excessive neuroplasticity burden triggers plaque and NFT formation. AD is said to exist when the density of both of these histopathological markers exceeds a certain threshold and when they are accompanied by dementia. Abbreviations: Aβ, β amyloid; AβPP, β amyloid precursor protein; ApoE, apolipoprotein E; NFT, neurofibrillary tangle; PS, presenilin. Neuron 1999 24, 521-529DOI: (10.1016/S0896-6273(00)81109-5)